Quinine 200 mg Film-Coated Tablets (DCP Start)
The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of its European generic portfolio.
Building on decades of experience in bringing high-quality, value-oriented pharmaceutical solutions to market, WELDING is pursuing this application in line with its structured and reliable approach to development and registration pathways, aiming to enable timely market access once the procedure is successfully completed.
This step underlines the company's commitment to reliable, responsible, and sustainable partnership models across the pharmaceutical value chain, and to improving patient access to essential medicines also for niche products. It further expands the company's Finished Dosage Form (FDF) portfolio. WELDING PHARMA FDF supports partners with value-oriented solutions ranging from development and market access support to long-term supply concepts.
“With the start of this procedure, we continue to strengthen our role as a reliable partner for the pharmaceutical industry,” said Lars Hallmayer, Managing Director, WELDING GmbH & Co. KG. “We thank all teams and partners involved for their expertise and dedication in reaching this milestone, and remain committed to transparent collaboration and long-term responsible business practices.”
The company views this initiative as part of its broader strategy to create sustainable economic value through trusted partnerships and international market expertise. With decades of experience in the pharmaceutical sector and a strong global network, WELDING PHARMA FDF works closely with partners to develop and implement tailored product and licensing solutions.
Further steps toward market availability will be taken in accordance with applicable national requirements, and updates will follow as the procedure progresses.
For media inquiries and partnership opportunities, please contact: https://weldinhttps://welding.eu/en/contact/contact-form-pharma-fdf/g.eu/...
